TGen News & Press Releases

Multi-year, 1143-patient genetic study identifies unique types of multiple myeloma

Posted Monday August 19, 2024

TGen-led group confirms high-risk subgroup among cancer patients

Gene set identifies glioblastomas most vulnerable to promising therapeutic

Posted Tuesday July 9, 2024

Multi-omics study looks at response to neddylation (NAE) inhibitor drugs

TGen Study Reveals Genetic Drivers of Common Liver Disease

Posted Thursday April 4, 2024

Meta-analysis points to potential new therapeutic pathways

Taking a Closer Look at Pulmonary Fibrosis Genetics

Posted Thursday March 28, 2024

Study is the first to map variations in gene regulation at the cell type level throughout the lung

Longevity scores show signs of resilience to certain diseases

Posted Wednesday March 27, 2024

Polygenic scores calculated by TGen researchers reflect both long life and health

Filter Study Dispels Common Myths About Valley Fever

Posted Tuesday February 13, 2024

Project in Phoenix metro area is first to look at fungus risk exposure in the air

Genome sequencing identifies factors that cause resistance to multiple myeloma T cell therapies

Posted Thursday August 31, 2023

Study suggests the problem is more common than previously thought

Erroneous genetic sequences identified for the first time in specific cells of ALS and frontotemporal dementia patients

Posted Wednesday July 19, 2023

Gene splicing defect known as “cryptic exons” detected using single-nuclei RNA sequencing

Novel Genetic Sequencing Technology Helps Researchers Find Answers in Cases of Pediatric Rare Disorders

Posted Monday July 10, 2023

The study identified likely cause of genetic disorder in six families

TGen-led study tracks infection and immunity across the universe of human viruses over time

Posted Monday April 3, 2023

Results offer glimpse into the future of forecasting infection and immunity

Prev
[1]
2
Next

Media Contact

Galen Perry
[email protected]
602-343-8423

Newsletter

News Archive

View Media Release Archive

OnCline

TGen is a partner with OncLive

2024 © All Rights Reserved TGen. Registered 501(c)(3). EIN: 75-3065445